Zheng C, Feng G, Liang H
Department of Radiology, Union Hospital, Tongji Medical University, Wuhan 430022, China.
Chin Med J (Engl). 1998 Dec;111(12):1060-3.
To evaluate Bletilla striata as a vascular embolizing agent in interventional treatment of primary hepatic carcinoma.
We made a vascular embolizing agent from a Chinese medicinal herb, Bletilla striata (bai ji). From October 1991 to January 1995, 56 patients with primary hepatic carcinoma were treated by hepatic arterial chemoembolization with Bletilla striata angioembolus, and 50 patients with primary hepatic carcinoma who were treated by conventional gelfoam embolization served as controls. All patients were followed up for 10-48 months.
Embolization with the Bletilla striata powder produced extensive and permanent vascular obstruction, resulting in marked shrinkage of the tumor and significant decrease of serum alpha fetoprotein (AFP) level. After embolization, less collateral circulation formed later. The treatment interval was prolonged to an average of 7 months. The 1-, 2- and 3-year survival rates were 81.9%, 44.9%, and 33.6%, respectively, with a mean survival period of 19.8 months. All the clinical parameters were better than those in the control group treated by conventional gelfoam embolization.
Bletilla striata angioembolus is a good vascular embolizing agent for treating PHC.
评估白及作为原发性肝癌介入治疗中的血管栓塞剂的效果。
我们用中药白及制作了一种血管栓塞剂。1991年10月至1995年1月，56例原发性肝癌患者接受了白及血管栓塞剂肝动脉化疗栓塞治疗，50例接受传统明胶海绵栓塞治疗的原发性肝癌患者作为对照。所有患者均随访10 - 48个月。
白及粉栓塞产生广泛且持久的血管阻塞，导致肿瘤明显缩小，血清甲胎蛋白（AFP）水平显著下降。栓塞后，后期形成的侧支循环较少。治疗间隔平均延长至7个月。1年、2年和3年生存率分别为81.9%、44.9%和33.6%，平均生存期为19.8个月。所有临床指标均优于接受传统明胶海绵栓塞治疗的对照组。
白及血管栓塞剂是治疗原发性肝癌的一种良好的血管栓塞剂。
